| Literature DB >> 21115552 |
Andrew Filer1, Paola de Pablo, Gina Allen, Peter Nightingale, Alison Jordan, Paresh Jobanputra, Simon Bowman, Christopher D Buckley, Karim Raza.
Abstract
OBJECTIVES: Early therapy improves outcomes in rheumatoid arthritis (RA). It is therefore important to improve predictive algorithms for RA in early disease. This study evaluated musculoskeletal ultrasound, a sensitive tool for the detection of synovitis and erosions, as a predictor of outcome in very early synovitis.Entities:
Mesh:
Year: 2010 PMID: 21115552 PMCID: PMC3033529 DOI: 10.1136/ard.2010.131573
Source DB: PubMed Journal: Ann Rheum Dis ISSN: 0003-4967 Impact factor: 19.103
Synovial intra-articular recesses and periarticular sites evaluated by ultrasound
| Joint | Recess or site |
|---|---|
| MCP (1–5), PIP (1–5), MTP (2–5) | Dorsal recess |
| Lateral recess (PIP, MCP 1,2,5 MTP 5) | |
| Volar recess (PIP) | |
| Wrist | Intercarpal recesses |
| Radiocarpal recesses | |
| Ulnarcarpal recesses | |
| Volar carpal recesses | |
| Elbow | Anterior recess |
| Humeroradial joint | |
| Humeroulnar joint | |
| Posterior recess | |
| Shoulder | Subdeltoid bursa |
| Posterior glenohumeral recess | |
| Knee | Suprapatellar recess |
| Medial parapatellar recess | |
| Lateral parapatellar recess | |
| Medial femorotibial joint line | |
| Lateral femorotibial joint line | |
| Ankle | Anterior tibiotalar recess |
| Medial tibiotalar recess | |
| Lateral tibiotalar recess |
MCP, metacarpophalangeal joint; MTP, metatarsophalangeal joint; PIP, proximal interphalangeal joint.
Baseline patient demographics and global clinical and ultrasound data
| Final diagnostic group by 1987 criteria | VERA | VENRA | Resolving |
|---|---|---|---|
| n | 29 | 13 | 16 |
| Final diagnosis, n (%) | |||
| RA | 29 (100) | 0 | 0 |
| PsA | 0 | 5 (38) | 1 (6.25) |
| SLE | 0 | 2 (15) | 0 |
| Parvovirus related | 0 | 0 | 1 (6.25) |
| Pseudogout | 0 | 0 | 1 (6.25) |
| Reactive | 0 | 1 (8) | 0 |
| Septic | 0 | 0 | 1 (6.25) |
| Unclassified | 0 | 5 (38) | 12 (75) |
| Age | 63 (19–82) | 45 (18–83) | 40 (23–75) |
| Female, n (%) | 13 (45) | 9 (69) | 10 (63) |
| Symptoms duration, weeks | 7 (2–12) | 6 (3–12) | 4 (1–9) |
| Morning stiffness, min | 120 (30–360) | 60 (0–240) | 52.5 (0–240) |
| NSAID use, n (%) | 20 (69) | 8 (62) | 13 (81) |
| RF positive, n (%) | 15 (52) | 2 (15) | 0 |
| ACPA positive, n (%) | 14 (48) | 0 | 0 |
| ESR (mm/h) | 25 (0–104) | 24 (4–87) | 21.5 (0–102) |
| CRP (mg/l) | 15 (0–102) | 16 (0–83) | 16 (0–244) |
| Swollen joint count of 66 | 8 (1–28) | 2 (1–13) | 1.5 (1–7) |
| Tender joint count of 68 | 9 (0–41) | 3 (0–19) | 2.5 (1–10) |
| DAS28 score | 4.49 (2.20–6.28) | 3.90 (1.66–6.27) | 3.57 (1.38–4.94) |
| Patients meeting ACR criteria at baseline | |||
| 1987 ACR criteria, n (%) | 12 (41) | 0 | 0 |
| USGS 1987 ACR criteria, n (%) | 16 (55) | 3 (23) | 1 (6) |
| 2010 ACR/EULAR criteria, n (%) | 24 (83) | 2 (15) | 0 |
| USGS 2010 ACR/EULAR criteria, n (%) | 27 (93) | 5 (38) | 2 (13) |
| Clinical pattern, n (%) | |||
| Monarthritis | 1 (3) | 6 (46) | 8 (50) |
| Oligoarthritis (2–5 joints) | 10 (34) | 6 (46) | 7 (44) |
| Polyarthritis (>5 joints) | 18 (62) | 1 (8) | 1 (6) |
| USGS pattern, n (%) | |||
| Monarthritis | 0 | 1 (8) | 0 |
| Oligoarthritis | 1 (3) | 2 (15) | 11 (69) |
| Polyarthritis | 28 (97) | 10 (77) | 5 (31) |
| US variables | |||
| GS index | 35 (5–78) | 14 (2–38) | 6 (2–19) |
| GS count of 38 | 15 (5–33) | 9 (1–20) | 3 (2–12) |
| PD index | 25 (5–60) | 9 (2–26) | 5.5 (0–16) |
| PD count of 38 | 12 (3–29) | 5 (1–13) | 3 (0–10) |
| Presence of erosions | |||
| Radiographic hand/foot erosion, n (%) | 1 (3.5) | 0 | 0 |
| US hand/foot erosion, n (%) | 11 (38) | 2 (15) | 0 |
| Any US erosion, n (%) | 11 (38) | 2 (15) | 1 (6.25) |
Median (range).
Clinical examination variables have been extended by adding ultrasonographic criteria of joint involvement (USGS grade ≥1) and erosion.
ACPA, anticyclic citrullinated peptide antibody; ACR, American College of Rheumatoloty; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; GS, greyscale ultrasound; NSAID, non-steroidal anti-inflammatory drug; PD, power Doppler; PsA, psoriatic arthropathy; RA, rheumatoid arthritis; RF, rheumatoid factor; SLE, systemic lupus erythematosus; US, ultrasound.
p<0.05,
p<0.01,
p<0.001 Kruskal–Wallis test.
Figure 1Clinical and ultrasound involvement by joint region. Joint region involvement, defined as the presence of at least one clinically swollen joint or one joint with ultrasound greyscale synovitis in a given region, in (A) the total cohort of very early arthritis patients, (B) patients who developed a diagnosis of rheumatoid arthritis (RA) and (C) an additional cohort of patients with newly presenting, untreated RA of greater than 3 months' symptom duration. (A) Ultrasound demonstrates increased sensitivity compared with clinical examination in all joints overall. (B) Significantly more clinically silent disease in patients developing RA is measured by ultrasound at the wrist, elbow, knee, ankle and metatarsophalangeal (MTP) joints. (C) Proximal interphalangeal joint (PIP), ankle and metatarsophalangeal joint disease is clinically more overt in patients with longer RA disease duration. MCP, metacarpophalangeal joint.
Sensitivity and specificity of clinical and ultrasound variables for the prediction of RA
| Sensitivity | Specificity | Positive LR | Negative LR | PPV | NPV | AUC | |
|---|---|---|---|---|---|---|---|
| MCP joints | |||||||
| MCP clinical involvement | 97 | 69 | 3 | 0.05 | 76 | 95 | 0.828 |
| MCP clinical symmetry | 65.5 | 97 | 19 | 0.36 | 95 | 74 | 0.810 |
| MCP GS ≥1 involvement | 100 | 38 | 2 | 0 | 62 | 100 | 0.690 |
| MCP GS ≥1 symmetry | 93 | 76 | 4 | 0.09 | 79 | 92 | 0.845 |
| MCP GS ≥2 involvement | 90 | 48 | 2 | 0.21 | 63 | 82 | 0.690 |
| MCP GS ≥2 symmetry | 86 | 79 | 4 | 0.17 | 81 | 85 | 0.828 |
| MCP GS count ≥8 | 45 | 100 | 0.55 | 100 | 64 | 0.724 | |
| MCP PD ≥1 involvement | 97 | 55 | 2 | 0.06 | 68 | 94 | 0.759 |
| MCP PD ≥1 symmetry | 83 | 79 | 4 | 0.22 | 80 | 82 | 0.810 |
| MCP PD ≥2 involvement | 90 | 66 | 3 | 0.16 | 72 | 86 | 0.776 |
| MCP PD ≥2 symmetry | 83 | 83 | 5 | 0.21 | 83 | 83 | 0.828 |
| PIP joints | |||||||
| PIP clinical involvement | 62 | 76 | 3 | 0.50 | 72 | 67 | 0.690 |
| PIP clinical symmetry | 41 | 93 | 6 | 0.63 | 86 | 61 | 0.672 |
| PIP GS ≥1 involvement | 79 | 62 | 2 | 0.33 | 68 | 75 | 0.707 |
| PIP GS ≥1 symmetry | 48 | 79 | 2 | 0.65 | 70 | 61 | 0.638 |
| PIP GS ≥2 involvement | 79 | 66 | 2 | 0.32 | 70 | 76 | 0.724 |
| PIP GS ≥2 symmetry | 48 | 90 | 5 | 0.58 | 82 | 63 | 0.690 |
| PIP PD ≥1 involvement | 76 | 69 | 2 | 0.35 | 71 | 74 | 0.724 |
| PIP PD ≥1 symmetry | 45 | 90 | 4 | 0.62 | 81 | 62 | 0.672 |
| PIP PD ≥2 involvement | 66 | 76 | 3 | 0.46 | 73 | 69 | 0.707 |
| PIP PD ≥2 symmetry | 38 | 97 | 11 | 0.64 | 92 | 61 | 0.672 |
| Wrist joints | |||||||
| Wrist clinical involvement | 69 | 86 | 5 | 0.36 | 83 | 74 | 0.776 |
| Wrist clinical symmetry | 48 | 93 | 7 | 0.56 | 88 | 64 | 0.707 |
| Wrist GS ≥1 involvement | 97 | 41 | 2 | 0.08 | 62 | 92 | 0.690 |
| Wrist GS ≥1 symmetry | 86 | 62 | 2 | 0.22 | 69 | 82 | 0.741 |
| Wrist GS ≥2 involvement | 79 | 69 | 3 | 0.30 | 72 | 77 | 0.741 |
| Wrist GS ≥2 symmetry | 52 | 93 | 7 | 0.52 | 88 | 66 | 0.724 |
| Wrist PD ≥1 involvement | 93 | 48 | 2 | 0.14 | 64 | 88 | 0.707 |
| Wrist PD ≥1 symmetry | 83 | 66 | 2 | 0.26 | 71 | 79 | 0.741 |
| Wrist PD ≥2 involvement | 90 | 48 | 2 | 0.21 | 63 | 82 | 0.690 |
| Wrist PD ≥2 symmetry | 69 | 72 | 2 | 0.43 | 71 | 70 | 0.707 |
| MTP joints | |||||||
| MTP clinical involvement | 17 | 100 | 0.83 | 100 | 55 | 0.586 | |
| MTP clinical symmetry | 10 | 100 | 0.90 | 100 | 53 | 0.552 | |
| MTP GS ≥1 involvement | 69 | 55 | 2 | 0.56 | 61 | 64 | 0.621 |
| MTP GS ≥1 symmetry | 55 | 79 | 3 | 0.56 | 73 | 64 | 0.672 |
| MTP GS ≥2 involvement | 59 | 72 | 2 | 0.57 | 68 | 64 | 0.655 |
| MTP GS ≥2 symmetry | 41 | 83 | 2 | 0.71 | 71 | 56 | 0.621 |
| MTP PD ≥1 involvement | 52 | 90 | 5 | 0.54 | 83 | 65 | 0.707 |
| MTP PD ≥1 symmetry | 35 | 100 | 0.66 | 100 | 60 | 0.672 | |
| MTP PD ≥2 involvement | 38 | 100 | 0.62 | 100 | 62 | 0.690 | |
| MTP PD ≥2 symmetry | 24 | 100 | 0.76 | 100 | 57 | 0.621 | |
| Other variables | |||||||
| Leiden score ≥8 | 62 | 93 | 9 | 0.41 | 90 | 71 | 0.776 |
| 1987 ACR criteria (4/7 clinical) | 79 | 90 | 8 | 0.23 | 89 | 81 | 0.845 |
| ACR criteria 4/7 GS | 93 | 65.5 | 3 | 0.10 | 73 | 91 | 0.793 |
| ACR criteria 4/7 PD | 86 | 76 | 4 | 0.18 | 78 | 85 | 0.810 |
| X-ray hand/foot erosion | 3.5 | 100 | 0.97 | 100 | 45 | 0.517 | |
| US hand/foot erosion | 38 | 93 | 5.5 | 0.67 | 85 | 60 | 0.655 |
| ACPA positive | 48 | 100 | 0.52 | 100 | 66 | 0.741 | |
| ACPA positive or MTP PD ≥2 Involvement or MCP GS count ≥8 | 76 | 100 | 0.24 | 100 | 81 | 0.879 | |
| PD10 index ≥10 | 79 | 93 | 11.5 | 0.22 | 92 | 82 | 0.862 |
ACPA, anti-cyclic citrullinated peptide antibody; ACR, American College of Rheumatology; AUC, area under the receiver operating characteristic curve; GS, ultrasound greyscale; LR, likelihood ratio; metacarpophalangeal joint (MCP) GS ≥1 involvement, MCP joint involvement with an ultrasound greyscale grade of at least 1; MCP joint GS count ≥8, at least eight MCP joints with GS involvement of grade ≥1; NPV, negative predictive value; PD, ultrasound power Doppler; PD10 index, summed power Doppler grades of MCP 2–3 joints, wrists and metatarsophalangeal (MTP) 2–3 joints; PIP, proximal interphalangeal joint; PPV, positive predictive value; RA, rheumatoid arthritis; US, ultrasound.
Impact of ultrasound on prediction of RA: multivariate analyses
| Variables | p Value | AUC |
|---|---|---|
AUC, area under the receiver operating characteristic curve; GS, ultrasound greyscale; GS count, sum of greyscale data when converted to a binary variable; GS index, sum of greyscale grades for all scanned joints; metacarpophalangeal (MCP) joint GS ≥1 involvement, MCP involvement with an ultrasound GS grade of at least 1; PD, ultrasound power Doppler; PD10 index, summed power Doppler grades of MCP joint 2–3 joints, wrists and metatarsophalangeal (MTP) 2–3 joints; RA, rheumatoid arthritis; US, ultrasound.
Figure 2Area under the receiver operating characteristic (ROC) curve for rheumatoid arthritis (RA) as an outcome using a 10-joint power Doppler index (summed power Doppler grades of metacarpophalangeal joints 2–3, wrists and metatarsophalangeal 2–3 joints) combined with the Leiden score (grey), versus the Leiden score alone (black). The 10-joint power Doppler index was entered as an explanatory variable in logistic regression analysis with an outcome of rheumatoid arthritis RA as the dependent variable and the Leiden score as the independent variable. The area under the ROC curve was compared using a non-parametric algorithm developed by DeLong et al.25